ACHE and Alzheimer disease: AChE inhibitors (rivastigmine, galantamine, and donepezil) and N‐methyl‐d‐aspartate (NMDA) receptor antagonists such as memantine are the mainstream drugs approved by the FDA for the treatment of AD;17 clinically, it cooperates with other metabolic enhancers, but these drugs are only symptomatic treatment and do not target key sites.